Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.

Annals of hematology - 1 Dec 2024

Zheng Shan, Tong Yuxin, Yang Linlin, Chen Jiayi, Tan Yamin

Abstract excerpt

Acute myeloid leukemia (AML) is the most prevalent hematologic malignancy in adults. In 2022, the European LeukemiaNet (ELN) has updated its prognostic system that incorporates cytogenetics and molecular genetics based on data from patients undergoing intensive chemotherapy (IC). Recently, a risk stratification framework has been established for hypomethylating agents (HMA)-based low-intensity treatment (LIT) to...

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Bridged Bicyclo Compounds, Heterocyclic
fms-Like Tyrosine Kinase 3
Isocitrate Dehydrogenase
Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39467855
DOI: 10.1007/s00277-024-06050-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.PMID 39467855Read ↗

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxSemantic proximity Read ↗

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity Read ↗

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.Semantic proximity Read ↗

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentSemantic proximity Read ↗

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.Semantic proximity Read ↗

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.Semantic proximity Read ↗

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New AgentsSemantic proximity Read ↗

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity Read ↗

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Semantic proximity Read ↗

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.